Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 2/2012

01-02-2012 | Original Research Article

Pharmacokinetics of a New Once-Daily Controlled-Release Formulation of Aceclofenac in Korean Healthy Subjects Compared with Immediate-Release Aceclofenac and the Effect of Food

A Randomized, Open-Label, Three-Period, Crossover, Single-Centre Study

Authors: Soo Kyung Bae, Soo-Hwan Kim, Hae Won Lee, Sook Jin Seong, Su-Yeon Shin, Sang Hun Lee, Mi-Sun Lim, Dr Young-Ran Yoon, Dr Hye Jung Lee

Published in: Clinical Drug Investigation | Issue 2/2012

Login to get access

Abstract

Background: A new controlled-release formulation of aceclofenac 200 mg (Clanza CR®) developed by Korea United Pharm., Inc., South Korea, for once-daily (od) dosing provides biphasic aceclofenac release consisting of immediate release of 85 mg followed by sustained release of 115 mg. Food has been known to affect the rate and extent of absorption of several drugs, in both immediate-release and controlled-release formulations.
Objective: The aim of this study was to evaluate the relative bioavailability of a new controlled-release formulation of aceclofenac (200 mg od; Clanza CR®) in comparison with immediate-release aceclofenac (100 mg twice daily [bid], Airtal®) and to assess the effect of food on the pharmacokinetics of the new controlled-release aceclofenac formulation.
Methods: This study was designed as a randomized, open-label, three treatment-period, crossover, single-centre study with a 1-week washout in 41 healthy adults. The three treatments consisted of immediate-release aceclofenac 100 mg bid administered under fasting conditions; controlled-release aceclofenac 200 mg od administered under fasting conditions; and controlled-release aceclofenac 200 mg od administered immediately after a standardized high-fat breakfast. Plasma concentrations of aceclofenac were determined using a highperformance liquid chromatography method.
Results: In the fasted state, the 90% confidence intervals (CIs) of the least squares geometric mean ratios (GMRs) for the area under the plasma concentration-time curve from time zero to 24 hours (AUC24) and the peak plasma concentration (Cmax) of aceclofenac for the controlled-release and immediate-release formulations of aceclofenac were all within the bioequivalence criteria range of 0.8–1.25. The 90% CIs of the GMRs for the AUC24 and Cmax of aceclofenac for the controlled-release formulation of aceclofenac in the fed and fasted states were also within the bioequivalence range. Both aceclofenac formulations were well tolerated in all subjects, and no serious adverse effects were observed.
Conclusion: The results demonstrate that controlled-release aceclofenac 200 mg is equivalent to immediate-release aceclofenac 100 mg when administered at the same total daily dose. Additionally, the bioavailability of controlled-release aceclofenac was not affected by high-fat foods.
Literature
1.
Brogden RN, Wiseman LR. Aceclofenac: a review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996; 52: 113–24PubMedCrossRef
2.
Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61: 1351–78PubMedCrossRef
3.
Grau M, Guasch J, Montero JL, et al. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneimittelforschung 1991; 41: 1265–76PubMed
4.
Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004; 5: 1347–57PubMedCrossRef
5.
Batlle-Gualda E, Figueroa M, Ivorra J, et al. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996; 23: 1200–6PubMed
6.
Kornasoff D, Maisenbacher J, Bowdler J, et al. The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol Int 1996; 15: 225–30PubMedCrossRef
7.
Llorente Melero MJ, Ten;ias Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig 2002; 94: 7–18PubMed
8.
Pasero G, Marcolongo R, Serni U, et al. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr Med Res Opin 1995; 13: 305–15PubMedCrossRef
9.
Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga JJ. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 1996; 15: 473–7PubMedCrossRef
10.
Kim YG, Lee YJ, Kim HJ, et al. Bioequivalence of two aceclofenac tablet formulations after a single oral dose to healthy male Korean volunteers. Int J Clin Pharmacol Ther 2001; 39: 83–8PubMed
11.
Najib N, Idkaidek N, Beshtawi M, et al. Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. Biopharm Drug Dispos 2004; 25: 103–8PubMedCrossRef
12.
Rhim SY, Park JH, Park YS, et al. Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers. Clin Ther 2008; 30: 633–40PubMedCrossRef
13.
Yong CS, Oh YK, Lee KH, et al. Trials of clear aceclofenac-loaded soft capsules with accelerated oral absorption in human subjects. Int J Pharm 2005; 302: 78–83PubMedCrossRef
14.
Bort R, Ponsoda X, Carrasco E, et al. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24: 834–41PubMed
15.
Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999; 289: 676–81PubMed
16.
Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000; 49: 133–8PubMedCrossRef
17.
Mutalik S, Manoj K, Reddy MS, et al. Chitosan and enteric polymer based once daily sustained release tablets of aceclofenac: in vitro and in vivo studies. AAPS PharmSciTech 2008; 9: 651–9PubMedCrossRef
18.
Mutalik S, Naha A, Usha AN, et al. Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac. Arch Pharm Res 2007; 30: 222–34PubMedCrossRef
19.
Pareek A, Chandurkar N, Gupta A, et al. Efficacy and safety of aceclofenac-CR and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. J Pain 2011; 12: 546–53PubMed
20.
Boullata JI, Armenti VT. Food effects on modified-release formulations. In: Boullata JI, Armenti VT, editors. Handbook of drug-nutrient interactions, 2nd ed. Totowa (NJ): Humana Press, 2010: 227–33CrossRef
21.
Kang W, Kim EY. Simultaneous determination of aceclofenac and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2008; 46: 587–91PubMedCrossRef
22.
Hermann M, Christensen H, Reubsaet JLE. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 2005; 382: 1242–9PubMedCrossRef
23.
Food and Drug Administration. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2002
24.
European Agency for the Evaluation of Medicinal Products. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). London: Human Medicines Evaluation Unit, 1999
25.
Movilia PG. Evaluation of the analgesic activity and tolerability of aceclofenac in the treatment of post-episiotomy pain. Drugs Exp Clin Res 1989; 15: 47–51PubMed
26.
Yscla A. Aceclofenac and paracetamol in episiotomal pain. Drugs Exp Clin Res 1988; 14: 491–4PubMed
27.
Honorato J, Caballero R, Giorgianni G, et al. Doseanalgesic response study and aceclofenac plasma levels in humans. Curr Ther Res Clin Exp 1990; 40: 605–11
28.
Cecchettin M, Cerea P, Torri G. Therapeutic efficacy of aceclofenac and diclofenac in acute knee arthroses: a study of E2-prostaglandin levels in synovial fluid and in serum. Clin Trials J 1988; 25: 144–51
Metadata
Title
Pharmacokinetics of a New Once-Daily Controlled-Release Formulation of Aceclofenac in Korean Healthy Subjects Compared with Immediate-Release Aceclofenac and the Effect of Food
A Randomized, Open-Label, Three-Period, Crossover, Single-Centre Study
Authors
Soo Kyung Bae
Soo-Hwan Kim
Hae Won Lee
Sook Jin Seong
Su-Yeon Shin
Sang Hun Lee
Mi-Sun Lim
Dr Young-Ran Yoon
Dr Hye Jung Lee
Publication date
01-02-2012
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 2/2012
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/11596530-000000000-00000

Other articles of this Issue 2/2012

Clinical Drug Investigation 2/2012 Go to the issue

Original Research Article

Three-Year Experience with Risedronate Therapy for Patients with an Increased Fracture Risk

Original Research Article

Implementing an Influenza Vaccination Programme for Adults Aged ≥ 65 Years in Poland

Short Communication

Effect of Oseltamivir on Bleeding Risk Associated with Warfarin Therapy

Original Research Article

Pharmacokinetics and Tolerability of Single and Multiple Doses of Ticagrelor in Healthy Chinese Subjects

Short Communication

Diagnosis of Depression and Use of Antidepressant Pharmacotherapy Among Adults in the United States

Correspondence

Capsaicin Instillation for Postoperative Pain following Total Knee Arthroplasty